WithdrawnPhase 2NCT02569125
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
Studying Overgrowth syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jochen Roessler
- Principal Investigator
- Jochen Roessler, ProfessorUniversity Hospital Freiburg
- Intervention
- Everolimus(drug)
- Eligibility
- 1 years · All sexes
- Timeline
- 2016 – 2016
Study locations (4)
- Vivantes Klinikum Neukölln, Berlin, Germany
- Universitätsklinikum Bonn, Bonn, Germany
- Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
- Universitätsklinikum Leipzig, Leipzig, Germany
Collaborators
Clinical Trials Unit Freiburg
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02569125 on ClinicalTrials.govOther trials for Overgrowth syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07145580Combined Lactulose H2-breath Test With Abdominal ImagingKlinik Arlesheim
- RECRUITINGPHASE1, PHASE2NCT06721884Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial OvergrowthNational University of Natural Medicine
- RECRUITINGNCT06710067Urine Metabolites in the Diagnosis of DiseaseLuventix, Inc.